Diabetes and CVD complications Karin Jandeleit-Dahm, MD, PhD, FRACP NHMRC Senior Research fellow Diabetes Complications Division Baker IDI Heart and Diabetes.

Slides:



Advertisements
Similar presentations
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
Advertisements

Aggressive Hyperglycemia Management. Significant hospital hyperglycemia requires close follow-up Previously diagnosed diabetes and elevated A1C Without.
Foos et al, EASD, Lisbon, 13 September 2011 Comparison of ACCORD trial outcomes with outcomes estimated from modelled and meta- analysis studies Volker.
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:
Canadian Diabetes Association Clinical Practice Guidelines Chronic Kidney Disease in Diabetes Chapter 29 Phil McFarlane, Richard E. Gilbert, Lori MacCallum,
1 Prediabetes Comorbidities and Complications. 2 Common Comorbidities of Prediabetes Obesity CVD Dyslipidemia Hypertension Renal failure Cancer Sleep.
Benefits of intensive multiple risk factor intervention.
Absolute cardiovascular disease risk Assessment and Early Intervention Dr Michael Tam Lecturer in Primary Care
Diabetes Mellitus Type 2
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Canadian Diabetes Association 2013 Clinical Practice Guidelines Targets for Glycemic Control Chapter 8 S. Ali Imran, Rémi Rabasa-Lhoret, Stuart Ross.
Diabetic Microvascular Disease: The Role of Glycemic Control and the Impact on Public Health Robert E. Ratner, MD MedStar Research Institute Georgetown.
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
RCS 6080 Medical and Psychosocial Aspects of Rehabilitation Counseling Diabetes and PVD.
Clinical Issues in the Management of Non Communicable Diseases Dr Gyaneshwar Rao Colonial War Memorial Hospital Suva.
Early Detection and Prevention of Renal Failure Linda Fried, MD, MPH.
ACCORD - Action to Control Cardiovascular Risk in Diabetes ADVANCE - Action in Diabetes to Prevent Vascular Disease VADT - Veterans Administration Diabetes.
Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.
Global impact of ischemic heart disease World Heart Federation, 2011.
HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol Simvastatin 20mg (10-40) vs. placebo FU 5 years  total cholesterol 25%;  LDL.
Therapy of Type 2 Diabetes Mellitus: UPDATE
20 Cardiovascular Disease and Physical Activity chapter.
Diabetes Mellitus Ibrahim Sales, Pharm.D. Assistant Professor of Clinical Pharmacy King Saud University
Blood glucose: is lower better for diabetic patients?
AN ASSESSMENT OF THE PRIMARY PREVENTION CONTROL PROGRAM OF PHC PREVENTIVE CARDIOLOGY CLINIC AMONG PATIENTS AT RISK FOR CVD: A Retrospective Cohort Study.
ACUTE STROKE — Hypertension is a common problem in patients with both type 1 and type 2 diabetes but the time course in relation to the duration.
Joint Effects of Routine Blood Pressure Lowering and Intensive Glucose Control ADVANCE Adapted from EASD 2008.
Hypertension the Community - Overview HYPERTENSION IN THE COMMUNITY: OVERVIEW.
Quality improvement in non glycaemic targets in diabetic patients at Central Australian Aboriginal Congress John Boffa Public Health Medical Officer.
Session II: Glycemic control, when the lower is not the better Strict glycemic control and cardiovascular diseases Stefano Genovese Diabetologia e Malattie.
1 NHLBI/NEI National Institutes of Health NHLBI/NEI National Institutes of Health.
VBWG HPS. Lancet. 2003;361: Gæde P et al. N Engl J Med. 2003;348: Recent statin trials: Reduction in primary outcome in patients with diabetes.
Diabetes Mellitus 101 for Medical Professionals An Aggressive Pathophysiologic Approach to Cardiometabolic Therapy for Type 2 Diabetes: Stan Schwartz MD,FACP.
FDA Endocrinologic and Metabolic Drugs Advisory Committee 1st June 2008 Rury Holman Clinical outcomes with anti-diabetic drugs: What we already know.
Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY.
The Burden and Contributors to Cardiovascular Disease and Diabetes in Indigenous Australians Alex Brown Baker IDI.
The ADVANCE trial: update and new results Jean-François Gautier Saint Louis Hospital, Paris 12 th Meeting of the Mediterranean Group for the Study of Diabetes.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.
Collaborative Atorvastatin Diabetes Study CARDS Dr Sachin Kadoo.
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
Impact of Diabetes on Cardiovascular Risk C.Richard Conti M.D. MACC Oct 16,2004 GWICC Beijing, PRC.
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
Therapy of Type 2 Diabetes Mellitus: UPDATE Glycemic Goals in the Care of Patients with Type 2 Diabetes ADA and AACE Guidelines: Room For Improvement.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015
An initiative of South Asian Federation of Endocrine Societies (SAFES)
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
Part 3. Diabetes Report Card: HbA 1c Levels in the United States Hoerger TJ, et al. Diabetes Care. 2008;31: Patients (%) HbA 1c (%)
Treatment of Hypertension in Adults With Diabetes DR AMAL HARFOUSH.
Ross T. Tsuyuki, BSc(Pharm), PharmD, MSc, FCSHP, FACC Yazid NJ Al Hamarneh, BPharm, PhD Charlotte Jones, MD, PhD, FRCP(C) Brenda Hemmelgarn, MD, PhD, FRCP(C)
The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.
Updates in Diabetic Nephropathy Rodica Pop-Busui, M.D., Ph.D Division of Metabolism, Endocrinology and Diabetes Michigan Comprehensive Diabetes Center.
The FAVORIT Study (Folic Acid for Vascular Outcome Reduction in Transplantation) Source Bostom AG, Carpenter MA, Kusek JW, et al. Homocysteine-lowering.
What should the Systolic BP treatment goal be in patients with CKD?
Diabetes type 2 Landmark Outcomes Trials
The SPRINT Research Group
Pathophysiology and Prevention of Heart Disease in Diabetes Mellitus
Hypertension Hanna K. Al-Makhamreh, MD FACC Interventional Cardiology.
Diabetes Health Status Report
AIM-HIGH Niacin Plus Statin to Prevent Vascular Events
Macrovascular Complications Microvascular Complications
Systolic Blood Pressure Intervention Trial (SPRINT)
Diabetes Journal Club March 17, 2011
Glycemic control for macrovascular disease in type II diabetes: Evidence and insights from recent trials  Sanjay Rajagopalan  Journal of Indian College.
The Clock is ticking for the world’s leaders
New frontiers in Diabetes management
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
EMPA-REG OUTCOME: Cumulative incidence of the primary outcome
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
Presentation transcript:

Diabetes and CVD complications Karin Jandeleit-Dahm, MD, PhD, FRACP NHMRC Senior Research fellow Diabetes Complications Division Baker IDI Heart and Diabetes Institute Melbourne

Micro-and macrovascular complications of diabetes Nephropathy Retinopathy Cardiovascular Disease High Risk Foot

AusDiab study CV mortality Circulation, 2007 * * *

From undernutrition to lifestyle diseases- shifting causes of death and disease   CV disease leading cause of death, relative mortality rates 3-4 times higher   Disproportionately higher rates of CKD and renal failure   Prevalence of overweight and obesity in Aboriginal adults is at least 40-45%   Incidence and prevalence of diabetes is at least 2-4 times higher (or higher)   Newly diagnosed diabetes in children in WA 18x higher in Indigenous children

Diabetes Prevalence in Indigenous Australians (35-44 years) as high as prevalence in other Australians > 55years Prevalence for CV disease increases rapidly: 16 % (35-44 years) 31 % (45-54 years) 47% >55Y years Heart, stroke, vascular disease, Australian facts, 2004 Differences in CVD risk profile

An epidemic of renal failure among Australian Aboriginals J Spencer et al, MJA 1998

The NEFRON study: National Evaluation of the Frequency of Renal Impairment cO-existing with NIDDM Baker IDI Heart and Diabetes Institute Kidney Health Australia Servier MC Thomas et al: The burden of chronic kidney disease in Australian patients with type 2 diabetes, MJA 2006

Micro-and macroalbuminuria NEFRON study M Thomas, MJA in 4 had eGFR < 60 ml/min 1 in 3 had ACR 27.3 % had microalbuminuria 7.3 % had macroalbuminuria NEFRON-results

M Thomas, MJA 2006 Higher frequency of macroalbuminuria in Indigenous Australians

The management of diabetes in Indigenous Australians from primary care Indigenous patients enrolled in NEFRON study I=144, NI= 449, TN=3893  60% vs 33% macrovascular disease  More established macrovascular disease  Poor glycaemic control (HbA1c > 8%, 55 %)  Smoking  LDL and BP similar M Thomas et al, BMC Public Health, 2007

The management of diabetes in indigenous Australians from primary care: The frequency of elevated urinary ACR Indigenous Total cohort Thomas M et al, BMC 2007

Frequency of macrovascular disease stratified for age and ethnicity M Thomas et al BMC % had 1 st degree relative with CVD < 50 years

Frequency of chronic kidney disease Stratitified for age and ethnicity M Thomas et al, BMC 2007

Diabetes Atherosclerotic vessel Normal aorta ? Diabetes is a major risk factor for CV disease

1. BP control 2. Lipids 3. Glucose 4. Inflammation Treatment and prevention of CV disease in diabetes

Cumulative incidence (%) ADVANCE-BP Effects on Mortality All cause mortality Cardiovascular death 0 10 Follow-up (months) Placebo Perindopril-indapamide 0 10 Follow-up (months) Placebo Perindopril-indapamide Relative risk reduction 18%; p=0.027 Relative risk reduction 14%; p=0.025

Summary – Main results, Blood pressure lowering comparison Routine treatment of type 2 diabetic patients with perindopril-indapamide resulted in: – 14% reduction in total mortality – 18% reduction in cardiovascular death – 9% reduction in major vascular events – 14% reduction in total coronary events – 21% reduction in total renal events

Glycemic Control and Diabetic Macrovascular Complications Epidemiologic data demonstrating a 2 – 4x increased in CVD outcomes Epidemiologic data demonstrating a 2 – 4x increased in CVD outcomes Blood Sugar Related to Lipoproteins, Syndrome X, Clotting, AGE, Renal Disease Therefore, improved glycemic control over a long period of time should lead to a decrease in CVD outcomes?

DCCT/EDIC Metabolic Results DCCT Intervention DCCT Intervention S t u d y Y e a r DCCT EDIC Observation EDIC ObservationTraining EDIC Conventional EDIC mean 8.2% Intensive EDIC mean 8.0% DCCT/EDIC Study Research Group, NEJM 2005

Conventional Intensive Non-Fatal MI, Stroke or CVD Death Cardiovascular Events Number at Risk Intensive: Conventional: Years from Study Entry Cumulative Incidence Risk reduction 57% 95% CI: 12, 79 Log-rank P = DCCT/EDIC Study Research Group, NEJM 2005

*p= Duckworth W et al for the VADT Investigators. N Engl J Med 2009; 360: 129–39. 2 The ACCORD Study Group N Engl J Med 2008;358: ; 3 The ADVANCE Collaborative Group N Engl J Med 2008,358: * Major 3 glucose lowering studies 2008 and CV disease

Risk ratio (95% CI) VADT ADVANCE UKPDS 0.94(0.80,1.10) 0.93(0.83,1.06) Favors intensive glucose controlFavors standard glucose control Hazard ratio (95% CI) Mortality (meta-analysis) 1.07(0.80,1.40) 1.22(1.01,1.46) ACCORD Overall Turnbull et al. Diabetologia in press Nov 2009

Diabetes Dyslipidaemia Hypertension Nutrition Exercise Clinical Population Basic Early life Pregnancy Childhood obesity Risk Factors SubClinical organ damage Arteries Heart Brain Kidneys Eyes etc Acute Complications Chronic Complications Heart Failure Terminal Disease Angina Kidney Failure Dementia Sudden Death Thrombosis Aneurysm

Prevent Prevent Diabetes Complications Metabolic imprinting/memory

Potential causes of diabetes-induced macrovascular disease Defective insulin action Hyperglycaemia Conventional risk factors Conventional risk factors Diabetes specific risk factors Diabetes specific risk factors Dyslipidaemia Hypertension Coagulopathy AGEs ROS Altered matrix Protein production Altered endothelium, SMCs, macrophages Goldberg, JCI, 2004

Formation of advanced glycation end products via the ‘Browning’ reaction Diet, smoking Glucose, Lipids, Inflammation “Ageing”

P21rasNFκB NTFαROS TGFβ1IL6 Background - AGE/RAGE pathway Heart/vessel stiffness MMP insensitivity Endothelial dysfunction Enzyme dysfunction Modified from Kass, D. A. (2003). Circ Res 92,

RR Macrophages Podocytes Epithelial Cells Mesangial Cells Endothelial Cells Cytokines (TNF, IL-1) Angiogenesis Cell Growth Growth Factors TGF , CTGF, PDGF Extracellular Matrix Protein Production Adapted Raj et al, AJKD, Cellular Responses Elicited by AGEs RAGE AGE-R 1-3 MSRs LOX-1 CD 36 Multispecfic AGE-receptors AGE

Can we stop diabetes and its complications without the prison of glycaemic control?

So which part is the most important? AGE/RAGE axis Renin Angiotensin System Oxidative Stress Blood pressure Dyslipidemia It is likely that combination approaches will be required No one pathway is sufficient to give all the answers Glucose control

Acknowledgements: The Diabetes Complications Group Merlin Thomas Mark Cooper